Rationale: Fibrosis leads to failure of the skin, lungs, and other organs in systemic sclerosis; accounts for substantial morbidity and mortality; and lacks effective therapy. Myofibroblast activation underlies organ fibrosis, but the key extracellular cues driving persistence of the process remain incompletely characterized. Objectives: The objectives were to evaluate activation of the IL6/JAK/STAT axis associated with fibrosis in skin and lung biopsies from systemic sclerosis patients and effects of the Food and Drug Administration-approved JAK/STAT inhibitor, tofacitinib, on skin and lung fibrosis in animal models. Methods: Bioinformatic analysis showed that IL6/JAK/STAT3 and tofacitinib gene signatures were aberrant in biopsies from systemic sclerosis patients in four independent cohorts. The results were confirmed by JAK and STAT3 phosphorylation in both skin and lung biopsies from patients with systemic sclerosis. Furthermore, treatment of mice with the selective JAK inhibitor tofacitinib not only prevented bleomycin-induced skin and lung fibrosis but also reduced skin fibrosis in TSK1/+ mice. Conclusion: These findings implicate the JAK/STAT pathway in systemic sclerosis skin and lung fibrosis and identify tofacitinib as a potential antifibrotic agent for the treatment of systemic sclerosis and other fibrotic diseases.
Rationale: Fibrosis leads to failure of the skin, lungs, and other organs in systemic sclerosis; accounts for substantial morbidity and mortality; and lacks effective therapy. Myofibroblast activation underlies organ fibrosis, but the key extracellular cues driving persistence of the process remain incompletely characterized. Objectives: The objectives were to evaluate activation of the IL6/JAK/STAT axis associated with fibrosis in skin and lung biopsies from systemic sclerosis patients and effects of the Food and Drug Administration-approved JAK/STAT inhibitor, tofacitinib, on skin and lung fibrosis in animal models. Methods: Bioinformatic analysis showed that IL6/JAK/STAT3 and tofacitinib gene signatures were aberrant in biopsies from systemic sclerosis patients in four independent cohorts. The results were confirmed by JAK and STAT3 phosphorylation in both skin and lung biopsies from patients with systemic sclerosis. Furthermore, treatment of mice with the selective JAK inhibitor tofacitinib not only prevented bleomycin-induced skin and lung fibrosis but also reduced skin fibrosis in TSK1/+ mice. Conclusion: These findings implicate the JAK/STAT pathway in systemic sclerosis skin and lung fibrosis and identify tofacitinib as a potential antifibrotic agent for the treatment of systemic sclerosis and other fibrotic diseases.
Authors: Jordan S Fridman; Peggy A Scherle; Robert Collins; Timothy C Burn; Yanlong Li; Jun Li; Maryanne B Covington; Beth Thomas; Paul Collier; Margaret F Favata; Xiaoming Wen; Jack Shi; Ryan McGee; Patrick J Haley; Stacey Shepard; James D Rodgers; Swamy Yeleswaram; Greg Hollis; Robert C Newton; Brian Metcalf; Steven M Friedman; Kris Vaddi Journal: J Immunol Date: 2010-04-02 Impact factor: 5.422
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Clara Dees; Michal Tomcik; Katrin Palumbo-Zerr; Alfiya Distler; Christian Beyer; Veronika Lang; Angelika Horn; Pawel Zerr; Jochen Zwerina; Kolja Gelse; Oliver Distler; Georg Schett; Jörg H W Distler Journal: Arthritis Rheum Date: 2012-09
Authors: Annie Moisan; Youn-Kyoung Lee; Jitao David Zhang; Carolyn S Hudak; Claas A Meyer; Michael Prummer; Sannah Zoffmann; Hoa Hue Truong; Martin Ebeling; Anna Kiialainen; Régine Gérard; Fang Xia; Robert T Schinzel; Kurt E Amrein; Chad A Cowan Journal: Nat Cell Biol Date: 2014-12-08 Impact factor: 28.824
Authors: Dinesh Khanna; Cristina Padilla; Lam C Tsoi; Vivek Nagaraja; Puja P Khanna; Tracy Tabib; J Michelle Kahlenberg; Amber Young; Suiyuan Huang; Johann E Gudjonsson; David A Fox; Robert Lafyatis Journal: JCI Insight Date: 2022-09-08